Abstract
Background: DKA requiring IV regular insulin infusion and close clinical and laboratory monitoring is the main cause of ICU admission and the main cause of inpatient resource utilization in children with Type1 DM. The recent increasingly used SC rapid-acting insulin analogue in the treatment of mild uncomplicated DKA has provided a safe and effective alternative to the standard IV insulin infusion. Currently, no comprehensive study that analyzed the different elements of DKA management cost effectiveness.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
